Literature DB >> 12614230

Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura.

Srdana Culić.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12614230     DOI： 10.1046/j.1365-2141.2003.04151_2.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

Review 1.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

Review 2.  The use of recombinant activated factor VII in platelet disorders: a critical review of the literature.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2009-01       Impact factor: 3.443

3.  7 Procoagulators.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 4.  Pathophysiology and therapeutic options in primary immune thrombocytopenia.

Authors:  Roberto Stasi
Journal:  Blood Transfus       Date:  2010-11-26       Impact factor: 3.443

5.  Use of Recombinant Factor VIIa in a Pediatric Patient With Initial Presentation of Refractory Acute Immune Thrombocytopenic Purpura and Severe Bleeding.

Authors:  Reut Gurion; Anita Siu; Aaron R Weiss; Margaret Masterson
Journal:  J Pediatr Pharmacol Ther       Date:  2012-07

6.  Postoperative pulmonary thromboembolism possibly associated with recombinant activated factor VII infusion for the treatment of uncontrolled hemorrhage during vertebral instrumentation.

Authors:  Zahid Hussain Khan; Alireza Ebrahim Soltani; Payman Rahmani
Journal:  J Anesth       Date:  2007-05-30       Impact factor: 2.078

7.  Long-term management of chronic immune thrombocytopenic purpura in adults.

Authors:  Javier Palau; Isidro Jarque; Miguel A Sanz
Journal:  Int J Gen Med       Date:  2010-10-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.